Though Isomorphic is burning through millions in R&D costs now, investors have high hopes for the potential of AI drug development.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
OpenAI allegedly issued overly-restrictive non-disclosure agreements that could penalize anyone who blows the whistle to government agencies.